TScan Therapeutics vs Taysha Gene Therapies
TCRX and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TCRX and TSHA compare
Taysha Gene Therapies is the larger company, worth 127 times as much as TScan Therapeutics ($1.3B against $10.2M).
TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −32.3% for Taysha Gene Therapies).
TScan Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1655% compared with −2728% at Taysha Gene Therapies.
Taysha Gene Therapies scores higher on the StockData Score (5 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TCRX | TSHA |
|---|---|---|
| Size and price | ||
| Market cap | $10.2M | $1.3B |
| Share price | $0.151 | $4.00 |
| Change, 1 year | −86.3% | −3.1% |
| Change, 5 years | −98.3% | −68.5% |
| Beta (5Y) | 2.15 | 2.80 |
| Employees | 142 | 99 |
| StockData Score | ||
| Total score | 4 | 5 (better) |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 238× |
| P/B | 0.1× (better) | 3.4× |
| FCF yield | −1157% | −10.2% (better) |
| Fair value | $1.36 | – |
| Margin of safety | 88.9% | – |
| Growth | ||
| Revenue growth (TTM) | 2.2% (better) | −32.3% |
| Revenue growth, 5Y average | 56.9% | – |
| Profitability | ||
| Operating margin | −1695% (better) | −2792% |
| Net margin | −1655% (better) | −2728% |
| FCF margin | −1666% (better) | −2417% |
| Return on equity | −95.8% | −47.1% (better) |
| Financial health | ||
| Debt / equity | 0.47 | 0.13 (better) |
| Interest coverage | −43.2× (better) | −3646.6× |
| Current ratio | 3.37 | 17.76 (better) |
| Altman Z-score | −6.31 | 7.07 (better) |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 53.5% | 91.9% |
| Held by insiders | 32.8% | 10.7% |
| Insider net buying, 12 months | $146K (better) | −$6.1M |
| Short interest, % of float | 4.4% | 18.4% |
Go deeper
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
- TSHA stock overview
- TSHA income statement
- TSHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.